Document is current
Any future updates will be listed below
-
Authors
García Megías, Irene https://orcid.org/0000-0001-9979-9227
Almeida, Ludmila Santiago https://orcid.org/0000-0002-6111-9246
Calapaquí Terán, Adriana K. https://orcid.org/0000-0001-7748-1955
Pabst, Kim M. https://orcid.org/0000-0002-9234-0795
Herrmann, Ken https://orcid.org/0000-0002-9662-7259
Giammarile, Francesco https://orcid.org/0000-0002-0550-7893
Delgado Bolton, Roberto C. https://orcid.org/0000-0002-8071-6513
- License Information
-
More Information
Article History
Received: 21 November 2024
Accepted: 22 January 2025
First Online: 11 March 2025
Declarations
:
: KH: Reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Fusion, personal fees from Immedica, personal fees from Onkowissen.de, personal fees from Novartis, personal fees from Molecular Partners, personal fees from ymabs, personal fees from Aktis Oncology, personal fees from Theragnostics, personal fees from Pharma15, personal fees from Debiopharm, personal fees from AstraZeneca, personal fees from Janssen. KMP: IPSEN (travel fees), Novartis (consultant, travel fees), Bayer (research funding), GE Healthcare (consultant), Clinician Scientist Stipend from the University Medicine Essen Clinician Scientist Academy (UMEA) sponsored by the faculty of medicine and Deutsche Forschungsgemeinschaft (DFG). The rest of the authors (IGM, LSA, AKCT, FG, and RCDB) report they have no conflict of interest.
: This study is a review. Therefore, this is not applicable.
: This study is a review. Therefore, this is not applicable.
